Abdul Mannan: Acquired Haemophilia A after Tozinameran
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“An isolated prolonged aPTT in an older patient.
No prior bleeding.
No anticoagulation.
Think carefully before you move on.
A patient presents with sudden bruising. No bleeding history. No anticoagulants.
Then the aPTT comes back prolonged. Isolated. And it doesn’t correct on mixing.
This is Acquired Haemophilia A. And it can happen after tozinameran.
Here’s what every clinician needs to know:
- AHA is rare overall, around 1.5 cases per million per year
- After tozinameran (Pfizer Comirnaty), estimated rate is 1 case per 4 million doses
- Most cases occur after dose 2, median onset around 23 days
- Skin involvement in 24 out of 27 reported cases
- Mortality sits between 8 and 20%
The proposed mechanism is molecular mimicry between the SARS-CoV-2 spike protein and FVIII sequences, triggering autoantibody production.
Diagnosis rests on three things. Isolated prolonged aPTT. Low FVIII activity. Positive Bethesda assay.
Management runs on two parallel tracks. Stop the bleeding first with FEIBA, rFVIIa, or tranexamic acid. Then target the inhibitor with steroids, cyclophosphamide if refractory, or rituximab.
One more thing. Re-exposure warning is real. Two of four re-exposed patients worsened. One died.
Extreme caution before any further tozinameran dose if vaccine-associated AHA is confirmed. Specialist haemophilia review is needed.
This does not change the overall vaccine benefit-risk balance. But pharmacovigilance matters.
Report suspected adverse reactions through the Yellow Card system.
Have you seen an unexpected prolonged aPTT in a recently vaccinated patient?”

More posts from Abdul Mannan on Hemostasis Today.
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 21:47Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention
-
Sep 29, 2026, 22:26A Global Call for Action on Cardiovascular Health on World Heart Day – ISTH